Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

Pre-chelated gallium-loaded polydopamine nanoparticles as a multifunctional regulator of osteoblast/osteoclastogenesis for the synergistic therapy of periodontitis

Jiang C., Chen X., Qin W., Gan N., Jiao T.

Animal Study on Chronic Inflammation, published in Mater Today Bio (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Mater Today Bio (2025)
Reported sample size
—
Source database
Europe PMC
PMID
41458180
PMCID
PMC12743557
DOI
10.1016/j.mtbio.2025.102638

Abstract (original English)

Periodontitis, a chronic inflammatory disease caused by local microbial dysbiosis and host immune imbalance, is prevalent on a global scale. Its progression is associated with an imbalance of pro- and anti-inflammatory cytokines, as well as osteoclast-mediated alveolar bone resorption. However, conventional non-surgical treatments exhibit limited efficacy due to the complex topography of periodontal pockets, instrumental limitations, antibiotic resistance, and the reliance on single-treatment strategies. This underscores the necessity for innovative therapeutic approaches. In this study, based on comprehensive treatment strategy of periodontitis, we designed and synthesized the pH-responsive PDA-Ga 3+ nanoparticles (PDA-Ga 3+ NPs) via a pre-chelated method. In vitro, PDA-Ga 3+ NPs significantly inhibited the growth and biofilm formation of Porphyromonas gingivalis while simultaneously suppressed the inflammatory response of macrophages induced by lipopolysaccharide from Porphyromonas gingivalis . Furthermore, the improvement in osteoblastogenesis by PDA-Ga 3+ NPs, as well as activation of Akt1-mTOR pathway reduced autophagy in preosteoclast and suppressed osteoclast formation, achieving dual regulation of bone remodeling. In vivo, PDA-Ga 3+ NPs inhibited autophagy in alveolar bone resorption, alleviated periodontitis progression, and reduced inflammatory cytokine expression in

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research